Glaxo-Theravance Lung Drug Gains Backing of FDA Advisers

GlaxoSmithKline Plc and Theravance Inc.’s Breo Ellipta should be approved to treat a lung disorder that is the third-leading cause of death in the U.S., advisers to the Food and Drug Administration said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.